Preclinical Identification of Sulfasalazine’s Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling

Approximately 25% of colorectal cancer (CRC) patients will develop metastatic (m)CRC despite treatment interventions. In this setting, tumor cells are attracted to the epidermal growth factor receptor (EGFR) oncogene. Kirsten rat sarcoma (RAS) 2 viral oncogene homolog (KRAS) mutations were reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Wai-Hung, Shih, Jing-Wen, Chen, Jian-Syun, Mokgautsi, Ntlotlang, Wei, Po-Li, Huang, Yan-Jiun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962339/
https://www.ncbi.nlm.nih.gov/pubmed/35203586
http://dx.doi.org/10.3390/biomedicines10020377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962339/
https://www.ncbi.nlm.nih.gov/pubmed/35203586
http://dx.doi.org/10.3390/biomedicines10020377

Ejemplares similares